Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Serono-Ono co-co- for go/no-go on so-so onco Stimuvax

This article was originally published in Scrip

Executive Summary

Merck Serono and Ono Pharmaceutical have signed a licence agreement providing Ono with co-development and co-marketing rights to Merck's investigational therapeutic cancer immunotherapy Stimuvax in Japan. Stimuvax (BLP25 liposome vaccine), which is designed to stimulate the body's immune system to target cancer cells that express the tumour antigen MUC-1, is in Phase III for the treatment of patients suffering from non-small cell lung cancer. Merck had originally obtained the exclusive worldwide licensing rights from Oncothyreon.

You may also be interested in...



Topotarget reconfirms mid-2013 US NDA for belinostat as it looks to Q3 milestone

Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).

AstraZeneca wins EU approval of rare thyroid cancer drug vandetanib

AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.

Solid but not spectacular: Victoza's weight loss verdict in non-diabetics

Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.

Topics

Related Companies

UsernamePublicRestriction

Register

OM016193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel